Wegovy (semaglutide), a licensed GLP-1 receptor agonist approved by the MHRA for chronic weight management, has demonstrated significant efficacy in clinical trials
However, a significant challenge in evaluating kidney outcomes lies in the inconsistent definitions of renal endpoints across studies, particularly regarding the thresholds for substantial eGFR decline, which vary from 30% to 57%
For adverse events and safety reporting, please reach out to: [email protected] any additional information related to Lilly products, please reach out to: [email protected]
The confusing part is that you may not feel hungry, but your body still needs food
Our experience shows that researchers who prioritize sourcing get the most reliable and reproducible data
Read on to learn more about the symptoms of SLE